Influence of <i>Bifidobacterium breve</i> on the Glycaemic Control, Lipid Profile and Microbiome of Type 2 Diabetic Subjects: A Preliminary Randomized Clinical Trial
Type 2 diabetes mellitus (T2DM) is one of the most highly prevalent metabolic disorders worldwide. Uncontrolled T2DM can lead to other health threats such as cardiac arrest, lower-limb amputation, blindness, stroke, impaired kidney function, and microvascular and macrovascular complications. Many st...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/16/5/695 |
| _version_ | 1797598678104408064 |
|---|---|
| author | Chaiyavat Chaiyasut Bhagavathi Sundaram Sivamaruthi Narissara Lailerd Sasithorn Sirilun Subramanian Thangaleela Suchanat Khongtan Muruganantham Bharathi Periyanaina Kesika Manee Saelee Thiwanya Choeisoongnern Pranom Fukngoen Sartjin Peerajan Phakkharawat Sittiprapaporn |
| author_facet | Chaiyavat Chaiyasut Bhagavathi Sundaram Sivamaruthi Narissara Lailerd Sasithorn Sirilun Subramanian Thangaleela Suchanat Khongtan Muruganantham Bharathi Periyanaina Kesika Manee Saelee Thiwanya Choeisoongnern Pranom Fukngoen Sartjin Peerajan Phakkharawat Sittiprapaporn |
| author_sort | Chaiyavat Chaiyasut |
| collection | DOAJ |
| description | Type 2 diabetes mellitus (T2DM) is one of the most highly prevalent metabolic disorders worldwide. Uncontrolled T2DM can lead to other health threats such as cardiac arrest, lower-limb amputation, blindness, stroke, impaired kidney function, and microvascular and macrovascular complications. Many studies have demonstrated the association between gut microbiota and diabetes development and probiotic supplementation in improving glycemic properties in T2DM. The study aimed to evaluate the influence of <i>Bifidobacterium breve</i> supplementation on glycemic control, lipid profile, and microbiome of T2DM subjects. Forty participants were randomly divided into two groups, and they received probiotics (50 × 10<sup>9</sup> CFU/day) or placebo interventions (corn starch; 10 mg/day) for 12 weeks. The changes in the blood-urea nitrogen (BUN), aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), fasting blood sugar (FBS), glycated hemoglobin (HbA1c), total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), creatinine levels, and other factors such as body-mass index, visceral fat, body fat, and body weight were assessed at baseline and after 12 weeks. <i>B. breve</i> supplementation significantly reduced BUN, creatinine, LDL, TG, and HbA1c levels compared to the placebo group. Significant changes were observed in the microbiome of the probiotic-treated group compared to the placebo group. Firmicutes and proteobacteria were predominant in the placebo and probiotic-treated groups. Genera <i>Streptococcus</i>, <i>Butyricicoccus</i>, and species <i>Eubacterium hallii</i> were significantly reduced in the probiotic-treated group compared to the placebo. Overall results suggested that <i>B. breve</i> supplementation could prevent worsening of representative clinical parameters in T2DM subjects. The current study has limitations, including fewer subjects, a single probiotic strain, and fewer metagenomic samples for microbiome analysis. Therefore, the results of the current study require further validation using more experimental subjects. |
| first_indexed | 2024-03-11T03:25:31Z |
| format | Article |
| id | doaj.art-7aafa27e9f1145d5b88175f6e773c70a |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-11T03:25:31Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-7aafa27e9f1145d5b88175f6e773c70a2023-11-18T02:48:36ZengMDPI AGPharmaceuticals1424-82472023-05-0116569510.3390/ph16050695Influence of <i>Bifidobacterium breve</i> on the Glycaemic Control, Lipid Profile and Microbiome of Type 2 Diabetic Subjects: A Preliminary Randomized Clinical TrialChaiyavat Chaiyasut0Bhagavathi Sundaram Sivamaruthi1Narissara Lailerd2Sasithorn Sirilun3Subramanian Thangaleela4Suchanat Khongtan5Muruganantham Bharathi6Periyanaina Kesika7Manee Saelee8Thiwanya Choeisoongnern9Pranom Fukngoen10Sartjin Peerajan11Phakkharawat Sittiprapaporn12Innovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, ThailandInnovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, ThailandInnovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, ThailandInnovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, ThailandInnovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, ThailandInnovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, ThailandInnovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, ThailandInnovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, ThailandNeuropsychological Research Laboratory, Neuroscience Research Center, School of Anti-Aging and Regenerative Medicine, Mae Fah Luang University, Bangkok 10110, ThailandNeuropsychological Research Laboratory, Neuroscience Research Center, School of Anti-Aging and Regenerative Medicine, Mae Fah Luang University, Bangkok 10110, ThailandInnovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, ThailandHealth Innovation Institute, Chiang Mai 50200, ThailandNeuropsychological Research Laboratory, Neuroscience Research Center, School of Anti-Aging and Regenerative Medicine, Mae Fah Luang University, Bangkok 10110, ThailandType 2 diabetes mellitus (T2DM) is one of the most highly prevalent metabolic disorders worldwide. Uncontrolled T2DM can lead to other health threats such as cardiac arrest, lower-limb amputation, blindness, stroke, impaired kidney function, and microvascular and macrovascular complications. Many studies have demonstrated the association between gut microbiota and diabetes development and probiotic supplementation in improving glycemic properties in T2DM. The study aimed to evaluate the influence of <i>Bifidobacterium breve</i> supplementation on glycemic control, lipid profile, and microbiome of T2DM subjects. Forty participants were randomly divided into two groups, and they received probiotics (50 × 10<sup>9</sup> CFU/day) or placebo interventions (corn starch; 10 mg/day) for 12 weeks. The changes in the blood-urea nitrogen (BUN), aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), fasting blood sugar (FBS), glycated hemoglobin (HbA1c), total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), creatinine levels, and other factors such as body-mass index, visceral fat, body fat, and body weight were assessed at baseline and after 12 weeks. <i>B. breve</i> supplementation significantly reduced BUN, creatinine, LDL, TG, and HbA1c levels compared to the placebo group. Significant changes were observed in the microbiome of the probiotic-treated group compared to the placebo group. Firmicutes and proteobacteria were predominant in the placebo and probiotic-treated groups. Genera <i>Streptococcus</i>, <i>Butyricicoccus</i>, and species <i>Eubacterium hallii</i> were significantly reduced in the probiotic-treated group compared to the placebo. Overall results suggested that <i>B. breve</i> supplementation could prevent worsening of representative clinical parameters in T2DM subjects. The current study has limitations, including fewer subjects, a single probiotic strain, and fewer metagenomic samples for microbiome analysis. Therefore, the results of the current study require further validation using more experimental subjects.https://www.mdpi.com/1424-8247/16/5/695diabetes mellitus<i>Bifidobacterium breve</i>probioticsmicrobiotalipid profile |
| spellingShingle | Chaiyavat Chaiyasut Bhagavathi Sundaram Sivamaruthi Narissara Lailerd Sasithorn Sirilun Subramanian Thangaleela Suchanat Khongtan Muruganantham Bharathi Periyanaina Kesika Manee Saelee Thiwanya Choeisoongnern Pranom Fukngoen Sartjin Peerajan Phakkharawat Sittiprapaporn Influence of <i>Bifidobacterium breve</i> on the Glycaemic Control, Lipid Profile and Microbiome of Type 2 Diabetic Subjects: A Preliminary Randomized Clinical Trial Pharmaceuticals diabetes mellitus <i>Bifidobacterium breve</i> probiotics microbiota lipid profile |
| title | Influence of <i>Bifidobacterium breve</i> on the Glycaemic Control, Lipid Profile and Microbiome of Type 2 Diabetic Subjects: A Preliminary Randomized Clinical Trial |
| title_full | Influence of <i>Bifidobacterium breve</i> on the Glycaemic Control, Lipid Profile and Microbiome of Type 2 Diabetic Subjects: A Preliminary Randomized Clinical Trial |
| title_fullStr | Influence of <i>Bifidobacterium breve</i> on the Glycaemic Control, Lipid Profile and Microbiome of Type 2 Diabetic Subjects: A Preliminary Randomized Clinical Trial |
| title_full_unstemmed | Influence of <i>Bifidobacterium breve</i> on the Glycaemic Control, Lipid Profile and Microbiome of Type 2 Diabetic Subjects: A Preliminary Randomized Clinical Trial |
| title_short | Influence of <i>Bifidobacterium breve</i> on the Glycaemic Control, Lipid Profile and Microbiome of Type 2 Diabetic Subjects: A Preliminary Randomized Clinical Trial |
| title_sort | influence of i bifidobacterium breve i on the glycaemic control lipid profile and microbiome of type 2 diabetic subjects a preliminary randomized clinical trial |
| topic | diabetes mellitus <i>Bifidobacterium breve</i> probiotics microbiota lipid profile |
| url | https://www.mdpi.com/1424-8247/16/5/695 |
| work_keys_str_mv | AT chaiyavatchaiyasut influenceofibifidobacteriumbreveiontheglycaemiccontrollipidprofileandmicrobiomeoftype2diabeticsubjectsapreliminaryrandomizedclinicaltrial AT bhagavathisundaramsivamaruthi influenceofibifidobacteriumbreveiontheglycaemiccontrollipidprofileandmicrobiomeoftype2diabeticsubjectsapreliminaryrandomizedclinicaltrial AT narissaralailerd influenceofibifidobacteriumbreveiontheglycaemiccontrollipidprofileandmicrobiomeoftype2diabeticsubjectsapreliminaryrandomizedclinicaltrial AT sasithornsirilun influenceofibifidobacteriumbreveiontheglycaemiccontrollipidprofileandmicrobiomeoftype2diabeticsubjectsapreliminaryrandomizedclinicaltrial AT subramanianthangaleela influenceofibifidobacteriumbreveiontheglycaemiccontrollipidprofileandmicrobiomeoftype2diabeticsubjectsapreliminaryrandomizedclinicaltrial AT suchanatkhongtan influenceofibifidobacteriumbreveiontheglycaemiccontrollipidprofileandmicrobiomeoftype2diabeticsubjectsapreliminaryrandomizedclinicaltrial AT murugananthambharathi influenceofibifidobacteriumbreveiontheglycaemiccontrollipidprofileandmicrobiomeoftype2diabeticsubjectsapreliminaryrandomizedclinicaltrial AT periyanainakesika influenceofibifidobacteriumbreveiontheglycaemiccontrollipidprofileandmicrobiomeoftype2diabeticsubjectsapreliminaryrandomizedclinicaltrial AT maneesaelee influenceofibifidobacteriumbreveiontheglycaemiccontrollipidprofileandmicrobiomeoftype2diabeticsubjectsapreliminaryrandomizedclinicaltrial AT thiwanyachoeisoongnern influenceofibifidobacteriumbreveiontheglycaemiccontrollipidprofileandmicrobiomeoftype2diabeticsubjectsapreliminaryrandomizedclinicaltrial AT pranomfukngoen influenceofibifidobacteriumbreveiontheglycaemiccontrollipidprofileandmicrobiomeoftype2diabeticsubjectsapreliminaryrandomizedclinicaltrial AT sartjinpeerajan influenceofibifidobacteriumbreveiontheglycaemiccontrollipidprofileandmicrobiomeoftype2diabeticsubjectsapreliminaryrandomizedclinicaltrial AT phakkharawatsittiprapaporn influenceofibifidobacteriumbreveiontheglycaemiccontrollipidprofileandmicrobiomeoftype2diabeticsubjectsapreliminaryrandomizedclinicaltrial |